Towards Healthcare
Small Nucleic Acid Drug Market to Reach at 18.84% CAGR till 2034

Small Nucleic Acid Drug Market 2025 Clinical Trials Rise

Projections indicate that, small nucleic acid drug industry is projected to rise from USD 5.94 billion in 2024 to USD 33.28 billion by 2034, reflecting a CAGR of 18.84% over the next decade. The rising prevalence of chronic disorders and the growing demand for personalized medicines bolster market growth. North America dominated the global market due to favorable regulatory support and increasing investments. 

Content

  • Insight Code: 6121
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The small nucleic acid drug market holds a valuation of USD 7.06 billion as of 2025, and will expand to USD 33.28 billion by 2034, achieving a CAGR of 18.84% between 2024 and 2034.

North America is leading the small nucleic acid drug market due to the availability of state-of-the-art research and development facilities, technological advancements, and favorable regulatory policies.

The small nucleic acid drug market includes six segments including by molecule type, by therapeutic area, by route of administration, by end-user, by distribution channel, and by region.

Some key players include Biogen, Inc., Arrowhead Pharmaceuticals, Wave Life Sciences, and OliX Pharmaceuticals.

Key trends include advances in genomic & proteomic technologies, increasing investments, and the rising prevalence of chronic disorders.

Government of Canada, Press Information Bureau, Food and Drug Administration, clinicaltrials.gov
Any Questions